A Study of Ivonescimab in People With Endometrial and Cervical Cancers

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Key Facts

Primary Endpoints (CT.gov)

Eligibility Criteria

Inclusion Criteria: * Histologically confirmed metastatic/recurrent endometrial or cervical cancer that has progressed after treatment with at least one platinum-based regimen. 1. Endometrial cancer histologies can include: endometrioid, serous, clear cell, dedifferentiated/undifferentiated, mixed epithelial, adenocarcinoma NOS, and carcinosarcoma. 2. Cervical cancer histologies can include: squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma * Measurable disease per RECIST v 1.1 criteria * Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2. * All patients must have received at least 1 line of platinum-based therapy. Prior PD1 or VEGF therapy is allowed. * Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤160/90 mmHg. * Have adequate laboratory values as defined in the following table: * Hematologic * Absolute neutrophil count (ANC) ≥1500/mm3 (≥1.5 × 103/µL…

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Source